GE Healthcare's Life Sciences business is on a mission to accelerate an age of molecular and precision medicine by providing expertise, tools and solutions for a wide range of applications. To enable the development and manufacture of high-quality biopharmaceuticals, vaccines and biologics, such as insulin, the business provides products, technologies, customized technical and commercial services, as well as the design and construction of complete biomanufacturing solutions. In addition to their leadership in bioprocessing, the business also offers tools for the basic research of cells and proteins, drug discovery, cell therapy and regenerative medicine, as well as leading contrast, PET and nuclear medicine agents for diagnostic imaging to help doctors make more informed diagnoses for better patient outcomes. The company's mission is to help enable a new era of molecular and precision medicine by providing customers with the technology, insight and knowledge to guide them ever more quickly from better biological understanding to better clinical therapies.
As part of the Johnson and Johnson Family of Companies in Ireland that employ nearly 3,000 people, Janssen are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology, haematology, immunology, neuroscience, infectious disease and cardiovascular and metabolic diseases. Driven by our commitment to patients, Janssen develops innovative products, services and healthcare solutions to help people throughout the world.
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and hemostasis products. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for the world's most challenging diseases. In Ireland, MSD employs approximately 1,600 people across our businesses in Carlow, Cork, Dublin and Tipperary, including manufacturing, R&D, commercial and marketing facilities in addition to global support services. A member of Guaranteed Irish, MSD is proud to be one of Ireland’s leading exporters. Many of the most widely used MSD medicines are developed by our teams in Ireland, with over half of MSD’s global top 20 products now manufactured here. MSD has a strong legacy in Ireland that stretches back over the last 50 years, and has seen the company invest over $2.5 billion in expanding and developing its facilities here. For further information please visit www.msd.ie